Foehr also pointed to movement in later-stage development, including Romantamig (formerly JNJ-5322), which he said “jumped from phase I to phase III” on the company’s pipeline chart. He described the asset as a tri-specific antibody being developed for multiple myeloma and said JNJ Innovative Medicine previously highlighted the program with “impressive clinical data.”Foehr highlighted several developments in the partner pipeline during the quarter, including an OmnidAb-derived program that progressed from p ...